Literature DB >> 11890333

Surgical treatment of schistosomal portal hypertension.

A A Ferraz1, T S Bacelar, M J Silveira, A R Coelho, R D Câmara Neto, J G de Araújo Júnior, E M Ferraz.   

Abstract

Schistosomiasis mansoni is a widespread parasitic disease in the Brazilian territory that affects over 8 million individuals. Hepatosplenic schistosomiasis is a serious clinical presentation of this disease, associated with splenomegaly, liver fibrosis, and portal hypertension, and is responsible for approximately 7% of schistosomotic patients. The surgical treatment of portal hypertension in schistosomotic patients has distinct features when compared with cirrhotic patients, mostly because hepatic function is preserved in schistosomotic liver disease. Therefore, when attempting to reduce the portal pressure, the surgeon must be aware that the surgery might interfere with hepatic perfusion, and consequently with hepatic function. The aim of this study was to report the results achieved with splenectomy, division of the left gastric vein, devascularization of great gastric curvature, and postoperative endoscopic variceal sclerosis, as a surgical option to esophageal varices in hepatosplenic schistosomiasis. A total of 111 patients were studied, and the following is a list of inclusion criteria: age >16 years, history of gastrointestinal (GI) bleeding, presence of esophageal varices on preoperative endoscopy, hematocrit >22% and prothrombin enzymatic activity >50%, negative viral hepatitis on serologic tests (anti-HBV and anti-HCV), and definition, after liver biopsy, of exclusive schistosomotic liver disease. The following list includes exclusion criteria used: presence of liver disease other than schistosomotic, history of alcohol abuse, and preoperative thrombosis of the portal vein. The rebleeding rate was 14.4% during a mean 30-month follow-up period; portal vein thrombosis was 13.2%, and there was a global mortality of 5.4%. Gastric varices were present in 46.9% of the patients; for those patients, a gastrotomy and running suture of the varices achieved an eradication rate of the varices of 75.6%. The degree of periportal fibrosis was also analyzed. Periportal fibrosis staging revealed that patients with class II or III liver fibrosis had a significant increased risk of recurrent GI bleeding when compared with patients with class I liver fibrosis. Despite the elevation on alanine aminotransferase (ALT) and aspartate aminotransferase (AST), most other liver function tests showed no alteration or were corrected after surgery. We conclude that splenectomy, division of the left gastric vein, devascularization of great gastric curvature, and postoperative endoscopic variceal sclerosis showed good results globally and should be considered as therapeutic options in the treatment of hepatosplenic schistosomiasis.

Entities:  

Mesh:

Year:  2001        PMID: 11890333

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  15 in total

1.  Fathal pulmonary hypertension after distal splenorenal shunt in schistosomal portal hypertension.

Authors:  Roberto de Cleva; Paulo Herman; Vincenzo Pugliese; Bruno Zilberstein; William-Abrão Saad; Joaquim-José Gama-Rodrigues
Journal:  World J Gastroenterol       Date:  2004-06-15       Impact factor: 5.742

2.  Long-term results of esophagogastric devascularization and splenectomy associated with endoscopic treatment in schistosomal portal hypertension.

Authors:  Fabio Ferrari Makdissi; Paulo Herman; Vincenzo Pugliese; Roberto de Cleva; William Abrão Saad; Ivan Cecconello; Luiz Augusto Carneiro D'Albuquerque
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

3.  Synchronous splenectomy and hepatectomy for patients with hepatocellular carcinoma and hypersplenism: A case-control study.

Authors:  Xiao-Yun Zhang; Chuan Li; Tian-Fu Wen; Lu-Nan Yan; Bo Li; Jia-Yin Yang; Wen-Tao Wang; Li Jiang
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

4.  Prognosis of endotherapy versus splenectomy and devascularization for variceal bleeding in patients with hepatitis B-related cirrhosis.

Authors:  Li Jiang; Hong-Shan Wei; Jia-Li Ma; Ling-Ling He; Ping Li
Journal:  Surg Endosc       Date:  2020-06-05       Impact factor: 4.584

5.  Splenic artery ligature associated with endoscopic banding for schistosomal portal hypertension.

Authors:  Renata Potonyacz Colaneri; Fabrício Ferreira Coelho; Roberto de Cleva; Marcos Vinícius Perini; Paulo Herman
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

6.  Doppler ultrasound could predict varices progression and rebleeding after portal hypertension surgery: lessons from 146 EGDS and 10 years of follow-up.

Authors:  Fabio Gonçalves Ferreira; Maurício Alves Ribeiro; Maria de Fátima Santos; José César Assef; Luiz Arnaldo Szutan
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

7.  Hepatic schistosomiasis.

Authors:  Karin L Andersson; Raymond T Chung
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12

8.  Late results of esophagogastric devascularization and splenectomy associated with endoscopic treatment in patients with schistosomiasis.

Authors:  Walter De Biase da Silva-Neto; Claudemiro Quireze-Júnior; Thiago Miranda Tredicci
Journal:  Arq Bras Cir Dig       Date:  2015 Jul-Sep

Review 9.  Diagnosis and clinical management of hepatosplenic schistosomiasis: A scoping review of the literature.

Authors:  Francesca Tamarozzi; Veronica A Fittipaldo; Hans Martin Orth; Joachim Richter; Dora Buonfrate; Niccolò Riccardi; Federico G Gobbi
Journal:  PLoS Negl Trop Dis       Date:  2021-03-25

10.  Splenectomy Improves Hemostatic and Liver Functions in Hepatosplenic Schistosomiasis Mansoni.

Authors:  Luiz Arthur Calheiros Leite; Adenor Almeida Pimenta Filho; Rita de Cássia dos Santos Ferreira; Caíque Silveira Martins da Fonseca; Bianka Santana dos Santos; Silvia Maria Lucena Montenegro; Edmundo Pessoa de Almeida Lopes; Ana Lúcia Coutinho Domingues; James Stuart Owen; Vera Lucia de Menezes Lima
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.